Literature DB >> 2918262

Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle.

J Isgaard1, A Nilsson, K Vikman, O G Isaksson.   

Abstract

Levels of mRNA for the insulin-like growth factor-I (IGF-I) in rat heart and skeletal muscle and its dependence on GH were investigated using a solution hybridization assay. Levels of IGF-I mRNA decreased following hypophysectomy, and replacement therapy with human GH (hGH) normalized heart and skeletal muscle levels. The stimulatory effect of hGH was dose-dependent, the lowest effective dose being 100 micrograms. A significant increase of IGF-I mRNA was observed 60 min after s.c. administration of 100 micrograms hGH and the maximum increase was apparent 6-12 h after hGH injection. Administration of 200 micrograms IGF-I or 11 micrograms insulin did not significantly change levels of IGF-I mRNA. The results show that GH regulates the level of IGF-I mRNA in rat heart and skeletal muscle and give further support to the hypothesis that locally produced IGF-I might be a local mediator for the direct stimulatory effect of GH on the growth and development of heart and skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918262     DOI: 10.1677/joe.0.1200107

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  23 in total

1.  A personal history of veterinary public health.

Authors:  J H Steele
Journal:  Vet Herit       Date:  1996-12

2.  Muscle IGF-I Ea, MGF, and myostatin mRNA expressions after compensatory overload in hypophysectomized rats.

Authors:  Akihiko Yamaguchi; Takahiko Fujikawa; Seita Shimada; Isao Kanbayashi; Masaru Tateoka; Hideaki Soya; Hidekatsu Takeda; Isao Morita; Kunio Matsubara; Toshihiro Hirai
Journal:  Pflugers Arch       Date:  2006-08-29       Impact factor: 3.657

Review 3.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

4.  The potential for growth hormone in the management of heart failure.

Authors:  J P Monson; G M Besser
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

5.  Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage.

Authors:  N Ozbey; A Oncül; Z Buğra; A Vural; F Erzengin; Y Orhan; K Büyüköztürk; E Sencer; S Molvalilar
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 6.  Insulin-Like growth factor I: implications in aging.

Authors:  E Arvat; F Broglio; E Ghigo
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

7.  Growth hormone signalling and apoptosis in neonatal rat cardiomyocytes.

Authors:  Y Gu; Y Zou; R Aikawa; D Hayashi; S Kudoh; T Yamauchi; H Uozumi; W Zhu; T Kadowaki; Y Yazaki; I Komuro
Journal:  Mol Cell Biochem       Date:  2001-07       Impact factor: 3.396

8.  Effects of insulin-like growth factor-I on the maturation of metabolism in neonatal rat cardiomyocytes.

Authors:  Christophe Montessuit; Tatiana Palma; Christelle Viglino; Corinne Pellieux; René Lerch
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

9.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men.

Authors:  M Hameed; K H W Lange; J L Andersen; P Schjerling; M Kjaer; S D R Harridge; G Goldspink
Journal:  J Physiol       Date:  2003-10-17       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.